Human Genome Wins Approval For Benlysta (HGSI)

by Jonathan Chen, Benzinga Staff Writer
March 9, 2011 5:26 PM | 13 seconds read |

Human Genome HGSI has received approval from the FDA for its lupus drug Benlysta, which is co-marketed with Glaxoo Smith Kline GSK.

Shares of Human Genome are trading at $25.55, and is still halted.

Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: NewsFDABiotechnologyHealth CarePharmaceuticals
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!